NCT01351519View on ClinicalTrials.gov

A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Malignant GliomaGliomaGlioblastomaGlioblastoma MultiformeAstrocytoma
Interventions
DRUG

Aminolevulinic Acid

Aminolevulinic Acid will be administered as a single oral dose of 20mg/kg given in 50ml of water three hours before surgery.

Trial Locations (1)

98405

MultiCare Health System Research Institute, Tacoma

Sponsors
All Listed Sponsors
lead

MultiCare Health System Research Institute

OTHER